Background In patients with severe asthma, tiotropium improves lung function and
exacerbation risk when added to high-dose inhaled corticosteroids plus long-acting β 2 …

Background Many patients with asthma remain symptomatic despite treatment with inhaled
corticosteroids (ICS) with or without long-acting β 2-agonists (LABAs). Tiotropium add-on to …

Background Some patients with asthma have frequent exacerbations and persistent airflow
obstruction despite treatment with inhaled glucocorticoids and long-acting beta-agonists …

Background Long-acting beta-agonist (LABA) therapy improves symptoms in patients whose
asthma is poorly controlled by an inhaled glucocorticoid alone. Alternative treatments for …

Background Tiotropium, a once-daily long-acting anticholinergic bronchodilator, has
demonstrated efficacy in patients with asthma who were symptomatic despite treatment with …

BACKGROUND: Some patients with severe asthma remain symptomatic and obstructed
despite maximal recommended treatment. Tiotropium, a long-acting inhaled anticholinergic …

BACKGROUND The role of tiotropium for the treatment of asthma has not yet been clearly
defined. The aim of this systematic review was to assess the efficacy and safety of tiotropium …

Introduction The objective of this paper is to systematically review the existing evidence of
the effectiveness and safety profile of a long-acting inhaled muscarinic antagonist as add-on …

Background Adding tiotropium to existing inhaled corticosteroid (ICS) maintenance therapy
with or without a long-acting β 2-agonist (LABA) has been shown to be beneficial in patients …

Background Tiotropium, a once-daily long-acting anticholinergic bronchodilator, when
administered via Respimat® SoftMist™ inhaler (tiotropium Respimat®) significantly reduces …